https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27681 Wed 11 Apr 2018 13:22:02 AEST ]]> Implications for dosimetric changes when introducing MR-guided brachytherapy for small volume cervix cancer: a comparison of CT and MR-based treatments in a single centre https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20297 cc for OAR and D₁₀₀, D₉₈ and D₉₀ for HR-CTV) were also considered. For patients with small HR-CTV sizes, introduction of MR-based volumetric brachytherapy produced a change in dose delivered to Point A and OAR. Point A doses fell by 4.8 Gy (p = 0.0002) and ICRU and D2cc doses for OAR also reduced (p < 0.01). Mean Point A doses for MR-based brachytherapy treatment plans were closer to those of HR-CTV D₁₀₀ for volumes less than 20 cm³ and HR-CTV D₉₈ for volumes between 20 and 35 cm³, with a significant difference (p < 0.0001) between Point A and HR-CTV D₉₀ doses in these ranges. In order to maintain brachytherapy dose consistency across varying HR-CTV sizes there must be a relationship between the volume of the HR-CTV and the prescription dose. Rather than adopting a ‘one size fits all’ approach during the transition to volume-based prescriptions, this audit has shown that separating prescription volumes into HR-CTV size categories of less than 20 cm³, between 20 and 35 cm³, and more than 35 cm³ the HR-CTV can provide dose uniformity across all volumes and can be directly linked to traditional Point A prescriptions.]]> Sat 24 Mar 2018 07:55:14 AEDT ]]> Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30211 Sat 24 Mar 2018 07:31:05 AEDT ]]>